Insilico Medicine has partnered with Servier in a multi-year R&D collaboration worth up to US$888 million to develop oncology therapies using AI-driven drug discovery platforms. Insilico stands to receive up to US$32 million in upfront and near-term R&D payments, and both companies will share research and development costs. Insilico has a strong pipeline of oncology programs, with two candidates in Phase I trials and four others out-licensed. The company has accelerated preclinical drug development timelines, nominating 20 preclinical candidates between 2021 and 2024 in just 12 to 18 months, setting a new efficiency benchmark in AI-driven drug R&D.

Read more at Nasdaq: Insilico Medicine Announces US$888 Mln Multi-Year Oncology Collaboration With Servier